File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Factors predicting outcome of fungal peritonitis in peritoneal dialysis: Analysis of a 9-year experience of fungal peritonitis in a single center

TitleFactors predicting outcome of fungal peritonitis in peritoneal dialysis: Analysis of a 9-year experience of fungal peritonitis in a single center
Authors
KeywordsCatheter removal
Issue Date2000
Citation
American Journal of Kidney Diseases, 2000, v. 36, n. 6, p. 1183-1192 How to Cite?
AbstractFungal peritonitis causes significant morbidity and mortality for patients undergoing continuous ambulatory peritoneal dialysis (CAPD). We retrospectively reviewed 70 episodes of fungal peritonitis in a single center over the last 9 years in 896 CAPD patients. Seventy percent of the episodes of fungal peritonitis were caused by Candida species, among which 50% were Candida parapsilosis. As a result of fungal peritonitis, 44% of the patients died, whereas further peritoneal dialysis failed in 14%, requiring a change to long-term hemodialysis. Only 37% managed to continue CAPD. The remaining 5% either underwent transplantation or were lost to follow-up. We identified the factors associated with poor outcome, namely mortality and technique failure. The presence of abdominal pain, bowel obstruction, and a catheter remaining in situ were significantly associated with greater mortality. Abdominal pain, antibiotic use within 3 months before fungal peritonitis, and complication by bowel obstruction were associated with greater technique failure. In choosing antifungal agents with catheter removal, oral fluconazole alone appears equally as effective as combined oral fluconazole with 5-flucytosine for peritonitis caused by Candida species. For peritonitis caused by species other than Candida, the choice of antifungal therapy needs to be individualized, based on fungal species and sensitivities. (C) 2000 by the National Kidney Foundation, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/228433
ISSN
2023 Impact Factor: 9.4
2023 SCImago Journal Rankings: 3.096
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorWang, Angela Yee Moon-
dc.contributor.authorYu, Alex Wai Yin-
dc.contributor.authorLi, Philip Kam Tao-
dc.contributor.authorLam, Peggo Kwok Wai-
dc.contributor.authorLeung, Chi Bon-
dc.contributor.authorLai, Kar Neng-
dc.contributor.authorLui, Siu Fai-
dc.date.accessioned2016-08-13T08:02:24Z-
dc.date.available2016-08-13T08:02:24Z-
dc.date.issued2000-
dc.identifier.citationAmerican Journal of Kidney Diseases, 2000, v. 36, n. 6, p. 1183-1192-
dc.identifier.issn0272-6386-
dc.identifier.urihttp://hdl.handle.net/10722/228433-
dc.description.abstractFungal peritonitis causes significant morbidity and mortality for patients undergoing continuous ambulatory peritoneal dialysis (CAPD). We retrospectively reviewed 70 episodes of fungal peritonitis in a single center over the last 9 years in 896 CAPD patients. Seventy percent of the episodes of fungal peritonitis were caused by Candida species, among which 50% were Candida parapsilosis. As a result of fungal peritonitis, 44% of the patients died, whereas further peritoneal dialysis failed in 14%, requiring a change to long-term hemodialysis. Only 37% managed to continue CAPD. The remaining 5% either underwent transplantation or were lost to follow-up. We identified the factors associated with poor outcome, namely mortality and technique failure. The presence of abdominal pain, bowel obstruction, and a catheter remaining in situ were significantly associated with greater mortality. Abdominal pain, antibiotic use within 3 months before fungal peritonitis, and complication by bowel obstruction were associated with greater technique failure. In choosing antifungal agents with catheter removal, oral fluconazole alone appears equally as effective as combined oral fluconazole with 5-flucytosine for peritonitis caused by Candida species. For peritonitis caused by species other than Candida, the choice of antifungal therapy needs to be individualized, based on fungal species and sensitivities. (C) 2000 by the National Kidney Foundation, Inc.-
dc.languageeng-
dc.relation.ispartofAmerican Journal of Kidney Diseases-
dc.subjectCatheter removal-
dc.titleFactors predicting outcome of fungal peritonitis in peritoneal dialysis: Analysis of a 9-year experience of fungal peritonitis in a single center-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.pmid11096043-
dc.identifier.scopuseid_2-s2.0-0033659990-
dc.identifier.volume36-
dc.identifier.issue6-
dc.identifier.spage1183-
dc.identifier.epage1192-
dc.identifier.isiWOS:000165721000014-
dc.identifier.issnl0272-6386-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats